MANNKIND CORP
About MANNKIND CORP
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $349.0M
- Net income
- $5.9M
- Total assets
- $792.2M
- Market cap
- $1.1B
- Gross margin
- 92.3%
- Operating margin
- 11.1%
- Net margin
- 1.7%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $349.0M
- Cost of revenue
- $26.8M
- Gross profit
- $322.2M
- Operating expenses
- $88.0M
- Operating income
- $38.8M
- Income tax
- -$4.5M
- Net income
- $5.9M
- EPS (basic)
- $0.02
- EPS (diluted)
- $0.02
Balance sheet
- Total assets
- $792.2M
- Current assets
- $291.6M
- Total liabilities
- $843.2M
- Current liabilities
- $171.0M
- Shareholders’ equity
- -$51.0M
Cash flow
- Operating cash flow
- $18.3M
- Investing cash flow
- -$304.8M
- Financing cash flow
- $315.1M
- Net cash flow
- $28.6M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.1B
- P/E ratio
- 169.5
- EPS (diluted)
- $0.02
- Shares outstanding
- 309.9M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Jul 28, 2004
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Profitable — net income of $5.9M in FY2025.
- Revenue grew 363% from FY2021 to FY2025.
- Gross margin of 92.3%, net margin 1.7%.
- Trading 45% below its 52-week high.
- Valued at a price-to-earnings (P/E) ratio of 169.5.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MANNKIND CORP.
Write a review
News about MANNKIND CORP
News & sentiment via Polygon.io
